So I've read the study. Essentially investigating whether extending some of the conventional T2 treatment protocols (to increase insulin sensitivity and preserve beta cells) to prediabetics will slow the progression to full-blown T2 diabetes. This is a small initial investigation. It is not the gold standard double-blind randomized control study. None the less, it did show some positive effects. If this were continued by a large pharma as a large RCT and shown sucessful, it could lead to an expansion of the drug labels.

It does not change anything for Afrezza, which I feel will change the way we treat diabetes even at the earliest stages.